CXCR5 (C-X-C Chemokine Receptor Type 5, also known as CD185, BLR1, and Munchen's) is a G protein-coupled receptor that binds specifically to the chemokine CXCL13 (also known as BLC, BCA-1, and B lymphocyte chemoattractant). Originally identified as essential for B cell trafficking to B cell follicles and germinal centers, CXCR5 and the CXCL13-CXCR5 axis have emerged as critical players in neuroinflammation, autoimmune diseases, and potentially in neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and multiple sclerosis [1][2].
The CXCL13-CXCR5 signaling axis orchestrates the organization of secondary lymphoid tissues, B cell follicle formation, and follicular helper T cell (Tfh) development. In the nervous system, this axis contributes to neuroinflammation through the recruitment of B cells and Tfh cells to the central nervous system, the formation of ectopic lymphoid structures in meninges, and the promotion of autoantibody production. This page covers the gene's normal function, molecular signaling mechanisms, disease associations, expression patterns in the brain, and therapeutic targeting strategies relevant to neurodegeneration.
| Property | Value |
|---|---|
| Gene Symbol | CXCR5 |
| Full Name | C-X-C Chemokine Receptor Type 5 |
| Aliases | CD185, BLR1, Munchen's, RB1 |
| Chromosomal Location | 11q23.3 |
| NCBI Gene ID | 935 |
| OMIM | 601745 |
| Ensembl ID | ENSG00000169679 |
| UniProt ID | P41970 |
| Gene Type | Protein coding |
| Gene Family | Chemokine receptors (GPCR family) |
The CXCR5 gene spans approximately 35 kb and consists of 5 exons encoding a 7-transmembrane domain GPCR of 372 amino acids. The gene is located on chromosome 11q23.3, a region that has been implicated in various malignancies and autoimmune diseases. The promoter region contains binding sites for multiple transcription factors including STAT5, BCL6, and NF-κB, reflecting its complex regulation in different immune cell types [3].
CXCR5 is a Class A G protein-coupled receptor consisting of:
The receptor binds CXCL13 with high affinity (Kd ~ 0.1-1 nM) and exhibits no significant binding to other chemokines. CXCL13 is unique among homeostatic chemokines in its specific pairing with CXCR5, making this axis particularly attractive for selective modulation [4].
Upon CXCL13 binding, CXCR5 activates multiple intracellular signaling pathways:
G protein-dependent signaling:
β-arrestin-dependent signaling:
Key downstream pathways:
The CXCR5 signaling axis is essential for the formation and maintenance of B cell follicles and germinal centers [5].
CXCR5 is essential for B cell migration and lymphoid tissue organization:
B cell follicle homing: CXCR5 expression on naive B cells guides them to B cell follicles in secondary lymphoid organs. The CXCL13 gradient created by follicular dendritic cells (FDCs) attracts CXCR5+ B cells, establishing the B cell follicle structure.
Germinal center formation: After antigen engagement, B cells upregulate CXCR5 and migrate to the follicular zone, where they interact with Tfh cells. This migration is essential for:
Marginal zone B cells: CXCR5 is expressed on marginal zone B cells, which are specialized for T-independent antibody responses to blood-borne antigens.
CXCR5 is a defining marker of Tfh cells and critical for their development:
Tfh differentiation: During CD4+ T cell activation, the balance between CXCR5 and CCR7 expression determines Tfh vs. non-Tfh fate. High CXCR5/low CCR7 favors Tfh differentiation.
Tfh migration: Tfh cells use CXCR5 to migrate into B cell follicles, where they provide help to B cells through:
Germinal center maintenance: Tfh cells are essential for germinal center maintenance, affinity selection, and memory B cell generation.
During development, CXCR5 is expressed on lymphoid tissue inducer (LTi) cells and is required for:
| Cell Type | CXCR5 Expression | Functional Significance |
|---|---|---|
| Naive B cells | High | Follicle homing |
| Memory B cells | Moderate | Follicle re-entry |
| Marginal zone B cells | High | T-independent responses |
| Tfh cells | High | Follicle migration, B cell help |
| Pre-Tfh cells | Moderate | Differentiation |
| NK T cells | Low | NKT cell trafficking |
| Dendritic cells (follicular) | Moderate | Antigen presentation |
In the healthy brain, CXCR5 expression is minimal. However, under pathological conditions:
B cells: CXCR5+ B cells are the primary CXCR5-expressing immune cells in the CNS. They accumulate in:
Tfh-like cells: CXCR5+ CD4+ T cells with Tfh-like phenotypes have been detected in:
Microglia: Some studies report low-level CXCR5 expression on microglia in demyelinating lesions, though this remains controversial.
Astrocytes: CXCL13 (the ligand) is expressed by astrocytes in various neurological conditions, creating a chemotactic gradient.
| Condition | CXCR5 Expression | Key Features |
|---|---|---|
| Multiple Sclerosis | High | B cells in lesions, ectopic follicles |
| Alzheimer's Disease | Moderate | B cells around plaques |
| Parkinson's Disease | Low-Moderate | B cells in substantia nigra |
| Stroke | Moderate | B cells in infarct area |
The CXCL13-CXCR5 axis is strongly implicated in multiple sclerosis pathogenesis:
B cell recruitment: CXCL13 is highly expressed in MS lesions, particularly in active demyelinating areas. The chemokine gradient recruits CXCR5+ B cells to the CNS, where they contribute to:
Ectopic lymphoid structures: B cells and Tfh-like cells form ectopic lymphoid-like structures in the meninges of progressive MS patients. CXCL13 expression by meningeal cells and astrocytes drives the organization of these structures, which correlate with:
Therapeutic implications: B cell depletion therapies (rituximab, ocrelizumab) may work in part by removing CXCR5+ B cells from CNS compartments. CXCR5 antagonists are being explored as targeted therapies [7][8].
| MS Disease Type | CXCR5/CXCL13 Role | Evidence Level |
|---|---|---|
| Relapsing-remitting MS | High | Strong |
| Secondary progressive | Very High | Strong |
| Primary progressive | Moderate-High | Moderate |
| Clinically isolated syndrome | High | Strong |
Emerging evidence links CXCR5 to Alzheimer's disease pathogenesis:
B cell infiltration: CXCR5+ B cells infiltrate AD brain and accumulate around amyloid plaques. These cells may contribute to:
Neuroinflammation: The CXCL13-CXCR5 axis contributes to chronic neuroinflammation in AD:
Cognitive decline: Correlative studies suggest associations between CSF CXCL13 levels and cognitive decline in AD patients [9][10].
| AD Feature | CXCR5 Association | Evidence |
|---|---|---|
| Amyloid plaques | CXCR5+ B cells surrounding plaques | Moderate |
| Neurofibrillary tangles | Unknown | Preliminary |
| Neuroinflammation | CXCL13 elevated in brain/CSF | Moderate |
| Cognitive decline | CSF CXCL13 correlates with decline | Preliminary |
CXCR5 involvement in Parkinson's disease is emerging:
Dopaminergic regions: CXCR5+ B cells have been detected in the substantia nigra of PD patients, though their role is unclear.
Neuroinflammation: CXCL13 expression is elevated in PD models and some patient samples. The axis may contribute to neuroinflammation through B cell recruitment.
Autoimmunity: Some studies suggest B cell autoimmunity in PD, and CXCR5+ Tfh cells may promote such responses.
| Condition | CXCR5/CXCL13 Involvement | Key Findings |
|---|---|---|
| Guillain-Barré Syndrome | Moderate | B cells in peripheral nerve |
| Myasthenia Gravis | High | Tfh cells in thymus |
| Amyotrophic Lateral Sclerosis | Preliminary | CXCL13 elevated in some studies |
| Stroke | Moderate | CXCL13 in ischemic tissue |
| Epilepsy | Preliminary | CXCL13 in seizure foci |
Beyond the nervous system, CXCR5 is implicated in:
Autoimmune diseases: Tfh cells expressing CXCR5 drive autoantibody production in:
Lymphoma: CXCR5 is expressed on certain B cell lymphomas, particularly:
Immunodeficiency: CXCR5 deficiency leads to impaired B cell follicle formation and immunodeficiency [11][12].
Several CXCR5-targeting strategies are in development:
Monoclonal antibodies:
Small molecule antagonists:
Alternative approaches:
While not directly targeting CXCR5, several approved therapies affect CXCR5+ cells:
Rituximab: Anti-CD20 antibody depletes B cells, including CXCR5+ populations. Used in MS, NHL, RA.
Ocrelizumab: Humanized anti-CD20 antibody approved for MS. Highly effective in RRMS and PPMS.
Ofatumumab: Anti-CD20 antibody with subcutaneous administration. Approved for MS.
Eculizumab/Ravulizumab: Anti-C5 antibodies used in PNH and MG, affect complement-mediated B cell functions [13].
CXCR5 knockout mice (Cxcr5-/-) exhibit:
CXCR5 overexpression in mice leads to:
The EAE model (mouse model of MS) has been used to study CXCR5: